Piflufolastat F 18: diagnostic first approval
SJ Keam - Molecular Diagnosis & Therapy, 2021 - Springer
Abstract Piflufolastat F 18 (PYLARIFY®) is an 18 F-labelled diagnostic imaging agent that
has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron …
has been developed by Progenics Pharmaceuticals Inc., a Lantheus company, for positron …
[HTML][HTML] Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the …
YJL Bodar, BGJC Zwezerijnen… - European journal of …, 2022 - Springer
Purpose Multiparametric magnetic resonance imaging (mpMRI) is a well-established
imaging method for localizing primary prostate cancer (PCa) and for guiding targeted …
imaging method for localizing primary prostate cancer (PCa) and for guiding targeted …